• Piezo1-Driven PANoptosis in Cardiac I/R Injury

  2026-08-28

  The reference study identifies Piezo1 as a mechanosensitive amplifier of myocardial ischaemia/reperfusion injury and links its activity to caspase-8-mediated cardiomyocyte PANoptosis. By combining an in vivo cardiac I/R model with hypoxia/reoxygenation experiments, the authors distinguish Piezo1-associated calcium influx from the caspase-8 requirement for PANoptotic signaling, providing a useful framework for mechanistic follow-up studies.

• Oleanolic Acid: A Smarter Liposome Assay Strategy

  2026-08-28

  Oleanolic acid can connect immune-pathway biology with rigorous liposome analytics. This guide explains how inducible nitric oxide synthase induction, formulation behavior, and nanoparticle exclusion HPLC can be interpreted without confusing encapsulation data with biological activity.

• Caveolin-1, Cholesterol Homeostasis, and MASLD

  2026-08-27

  The reference study identifies Caveolin-1 as a regulator of hepatic cholesterol homeostasis that limits MASLD progression by engaging the FXR/NR1H4–ABCG5/ABCG8 axis. Its combination of CAV1-deficient mice, liver transcriptomics, human samples, and cell-based experiments links cholesterol accumulation with endoplasmic reticulum stress and pyroptosis, offering a mechanistic framework for future validation.

• N-octanoyl-L-Homoserine lactone in Cell Assays

  2026-08-27

  This scenario-driven guide explains how N-octanoyl-L-Homoserine lactone (SKU C3579) can be incorporated into viability, proliferation, cytotoxicity, and infection-biology workflows without confusing metabolic or growth effects with cell death. It covers solvent controls, concentration planning, interpretation, and practical vendor-selection criteria supported by product data and recent C8-HSL research.

• ECL Chemiluminescent Substrate Detection Kit for RCC

  2026-08-26

  Translate RCC metabolism findings into sharper western blot chemiluminescence detection with low-picogram sensitivity, low background, and a signal window lasting up to 5 hours. This workflow shows how to test LDHA, HIF-1α, VEGFA, and VEGFR2 responses while preserving quantitative discipline across sensitive and resistant cell models.

• Potassium Iodide for Reliable Cell Assays

  2026-08-26

  Potassium Iodide (SKU B2008) can help researchers standardize iodide-dependent experiments, solution preparation, and assay controls across thyroid and cell-based workflows. This scenario-driven guide explains its documented solubility, storage, purity, and limitations so scientists can make defensible, reproducible reagent decisions.

• Entecavir (BMS200475) HBV Research Workflows

  2026-08-25

  Build reproducible HBV replication assays with Entecavir by pairing dose-response testing, resistant-strain comparisons, viral DNA quantification, and cytotoxicity controls. This workflow also separates cell-based potency from animal and clinical translation, helping researchers avoid the evidence gaps highlighted in antiviral studies.

• Pam3CSK4: Precision TLR1/2 Agonist

  2026-08-25

  Pam3CSK4 is a synthetic TLR1/2 agonist for controlled innate immune stimulation. It supports macrophage nitric oxide production, TNF-α induction, platelet activation studies, and allergic airway inflammation models, while remaining distinct from the TRPV1-dependent neuroimmune pathway described in recent work.

• Glutamine Metabolism and SIRT4 in Liver Fibrosis

  2026-08-24

  The reference study identifies hepatic stellate cell glutamine catabolism as a therapeutic vulnerability in liver fibrosis and positions mitochondrial SIRT4 as an endogenous brake on GDH activity. Its combined pharmacological and genetic evidence links reduced glutamate-to-α-ketoglutarate flux with lower stellate-cell proliferation and fibrosis, while also defining important limits for translating the mechanism to mitochondrial quality-control studies.

• ASB3 Suppresses Antiviral Immunity Through MAVS Loss

  2026-08-24

  The reference study identifies ASB3 as an inducible E3 ubiquitin ligase that weakens antiviral innate immunity by directing MAVS toward K48-linked polyubiquitination and proteasomal degradation. Its gain- and loss-of-function experiments, together with influenza infection models, connect ASB3 activity to reduced interferon signaling and increased viral susceptibility.

• 3X FLAG Peptide: Tagging, Detection, and Purification

  2026-08-23

  The 3X (DYKDDDDK) Peptide is a hydrophilic tandem FLAG epitope designed for sensitive detection and affinity workflows. Its reported solubility, antibody-recognition profile, storage conditions, and metal-dependent behavior support recombinant-protein research, but assay-specific validation remains essential.

• PP 2 (AG 1879): Reading Src Signals in ROS Assays

  2026-08-22

  PP 2 (AG 1879) is a selective Src-family kinase probe for cancer research, immune signaling, and pathway dissection. This article explains how a vascular ROS study changes PP 2 assay design, concentration selection, and interpretation of causality.

• Substance P: From NK-1 Biology to Assay Design

  2026-08-22

  Substance P is a tachykinin neuropeptide central to pain transmission research, neuroimmune signaling, and inflammation studies. This guide connects NK-1 receptor biology with practical peptide handling and explains how spectral-interference research can improve assay quality without replacing functional validation.

• Macrophage EV miR-660 Drives Breast Cancer Metastasis

  2026-08-21

  The reference study defines a macrophage-to-tumor communication pathway in which extracellular vesicles transfer miR-660 into breast cancer cells, suppressing KLHL21 and activating the IKKβ/NF-κB p65 axis. By combining tissue analyses, mechanistic cell experiments, extracellular-vesicle co-culture, and mouse metastasis models, it provides a coherent framework for understanding how tumor-associated macrophages promote breast cancer invasion.

• Bile Acid Retention and Immune Escape in MASH-HCC

  2026-08-20

  A 2026 Cancer Letters study identifies a GPR120–FXR/ABCB11–bile acid–NLRC5 pathway that links lipid-associated metabolic dysfunction to defective MHC-I antigen presentation in MASH-HCC. Its findings suggest that reducing intracellular bile acid retention can restore tumor antigenicity and improve anti-PD-1 responses, while also providing a framework for mechanistic antigen-presentation assays.

8311 records 1/555 page Next 12345 下5页 Last page